ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Lipoglycopeptide (Long-Acting ABSSSI / MRSA) Pregnancy: Avoid — insufficient human data. MRSA SSTI in pregnancy: discuss with ID specialist for alternative; vancomycin has more safety data in pregnancy.

Dalbavancin

Brand names: Xydalba

Adult dose

Dose: Single dose: 1500 mg IV once. OR two-dose: 1000 mg on day 1, then 500 mg on day 8
Route: Intravenous (infuse over 30 minutes)
Frequency: Single weekly or two-dose regimen
Max: 1500 mg (single dose)
Acute bacterial skin and skin structure infections (ABSSSI) including MRSA. Extended half-life (~346 hours) allows weekly dosing. Single 1500 mg dose equivalent to 2-week IV vancomycin course. Eliminates need for prolonged hospitalisation or OPAT — major advantage for MRSA SSTI. Source: BNF 90; NICE TA543; MHRA SPC Xydalba.

Paediatric dose

Dose: Not licensed under 18 years N/A/kg
Route: N/A
Frequency: N/A
Max: N/A
Not licensed for paediatric use.

Dose adjustments

Renal

eGFR <30 mL/min (not on dialysis): reduce to 1125 mg single dose or 750 mg + 375 mg two-dose regimen. On haemodialysis: no dose adjustment (dalbavancin is not appreciably dialysed — lipophilic protein binding).

Hepatic

Child-Pugh A/B: no adjustment. Child-Pugh C: not studied — use with caution.

Paediatric weight-based calculator

Not licensed for paediatric use.

Clinical pearls

  • Ultra-long half-life — the defining pharmacokinetic property: dalbavancin has a terminal half-life of approximately 346 hours (14.4 days). A single 1500 mg IV dose maintains plasma concentrations above MRSA MIC90 for 2 weeks. This enables same-day discharge after IV infusion — transformative for ABSSSI management and resource utilisation.
  • DISCOVER trials: dalbavancin single-dose (1500 mg) was non-inferior to vancomycin 14-day course for ABSSSI (cure rates 82.4% vs 80.7%). No vancomycin TDM required, no daily IV access needed. Particularly valuable for patients requiring OPAT who lack IV access or live far from home.
  • NICE TA543: recommended as an option for ABSSSI in adults where MRSA coverage is required and daily IV treatment is impractical or not feasible. Cost-effective vs inpatient vancomycin despite higher drug acquisition cost — hospitalisation savings exceed drug costs.
  • Red Man Syndrome prevention: infuse over 30 minutes minimum. If patient develops flushing or pruritus — slow infusion rate and premedicate with diphenhydramine for subsequent doses. True anaphylaxis (IgE-mediated) is rare; Red Man Syndrome is rate-dependent.
  • Endocarditis and bone/joint infections — off-label emerging use: dalbavancin's long half-life is being explored for step-down therapy after initial IV treatment in endocarditis (single weekly dose as outpatient vs 6-week OPAT). Early data promising. Not currently licensed for this indication. Source: BNF 90; NICE TA543; Boucher et al. Clin Infect Dis 2014 (DISCOVER); MHRA SPC Xydalba.

Contraindications

  • Hypersensitivity to glycopeptide antibiotics (vancomycin cross-reactivity possible — check allergy)
  • VRE (vancomycin-resistant Enterococcus) infections — dalbavancin also inactive against VRE (same target — D-Ala-D-Lac modification)

Side effects

  • Nausea, headache, diarrhoea (most common — 5–10%)
  • Elevated LFTs
  • Pruritus, rash
  • Infusion-related reactions (Red Man Syndrome — infuse over minimum 30 minutes; may premedicate with antihistamine)
  • Flushing, hypotension (rate-dependent Red Man Syndrome)

Interactions

  • No significant pharmacokinetic drug-drug interactions — dalbavancin is not a CYP substrate or inducer
  • Concomitant nephrotoxics: additive nephrotoxicity theoretically — monitor renal function

Monitoring

  • Clinical response at 48–72h (ABSSSI — lesion size, systemic signs)
  • Renal function (eGFR) — dose adjustment if eGFR <30 mL/min
  • LFTs at baseline
  • Culture and susceptibility (confirm dalbavancin MIC if MRSA — MIC ≤0.125 mg/L is susceptible)
  • No vancomycin-level monitoring needed — unlike vancomycin

Reference: BNFc; BNF 90; NICE TA543; Boucher et al. Clin Infect Dis 2014 (DISCOVER I/II); MHRA SPC Xydalba. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways